PE20010648A1 - Derivados de quinolin-4-ilo amino u oxi - Google Patents
Derivados de quinolin-4-ilo amino u oxiInfo
- Publication number
- PE20010648A1 PE20010648A1 PE2000001024A PE0010242000A PE20010648A1 PE 20010648 A1 PE20010648 A1 PE 20010648A1 PE 2000001024 A PE2000001024 A PE 2000001024A PE 0010242000 A PE0010242000 A PE 0010242000A PE 20010648 A1 PE20010648 A1 PE 20010648A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- quinolin
- phenyl
- amino
- ilamino
- Prior art date
Links
- -1 AMINO Chemical class 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 abstract 2
- 150000003973 alkyl amines Chemical class 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- XPNJWYYAPBKDAQ-UHFFFAOYSA-N 2-amino-1-(6-chloro-2-phenylquinolin-4-yl)butan-1-ol Chemical compound N=1C2=CC=C(Cl)C=C2C(C(O)C(N)CC)=CC=1C1=CC=CC=C1 XPNJWYYAPBKDAQ-UHFFFAOYSA-N 0.000 abstract 1
- YFBMGEUUCADRTG-UHFFFAOYSA-N 2-amino-1-(6-methyl-2-phenylquinolin-4-yl)butan-1-ol Chemical compound N=1C2=CC=C(C)C=C2C(C(O)C(N)CC)=CC=1C1=CC=CC=C1 YFBMGEUUCADRTG-UHFFFAOYSA-N 0.000 abstract 1
- WZKSXHQDXQKIQJ-UHFFFAOYSA-N F[C](F)F Chemical class F[C](F)F WZKSXHQDXQKIQJ-UHFFFAOYSA-N 0.000 abstract 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 abstract 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical class O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical group [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 239000003087 receptor blocking agent Substances 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A QUINOLIN-1-IL SUSTITUIDOS, DE FORMULA I, DONDE R1 ES H, ALQUILO, ALCOXILO, OH, AMINO, NITRO, CIANO, ALQUIL-AMINO, DIALQUILAMINO, HALOGENO, ENTRE OTROS; R2 ES FENILO OPCIONALMENTE SUSTITUIDO CON ALQUILO, ALCOXILO, HALOGENO, TRIFLUOROMETILO, AMINO, ALQUILAMINO, ENTRE OTROS; R3 Y R4 SON H, ALQUILO; R3 ES H, ALQUILO, CH2OH, CH2NR6R7; R6 Y R7 SON H, ALQUILO, (CH2)n-FENILO, CICLOALQUILO, (CH2)m-MORFOLINO, O JUNTO CON N FORMAN UN ANILLO SATURADO C4-C6; n ES 0-3; m ES 2-3; X ES NR8, O; X Y R5 SON N(CH2)2-, X Y R3 SON N(CH2)3; R8 ES H, ALQUILO, EXCEPTO LOS COMPUESTOS (6-CLORO-2-FENIL-4-QUINOLINIL)-(+)-2-AMINOBUTANOL, (6-METIL-2-FENIL-4-QUINOLINIL)-(+)-2-AMINOBUTANOL, ENTRE OTROS. SON COMPUESTOS PREFERIDOS 2-{2-(3,4-DIHIDRO-1H-ISOQUINOLIN-2-IL)-QUINOLIN-4-ILAMINO)-ETANOL, (RS)-1-AMINO-3-(2-p-TOLIL-QUINOLIN-4-ILAMINO)PROPAN-2-OL, (RS)-1-(7-METOXI-2-FENIL-QUINOLIN-4-ILOXI)-3-METILAMINO-PROPAN-2-OL, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. EL COMPUESTO I ES UN BLOQUEADOR SELECTIVO DEL RECEPTOR N-METIL-D-ASPARTATO (NMDA) Y PUEDE SER UTIL PARA EL TRATAMIENTO DE FORMAS AGUDAS DE NEURODEGENERACION, ALZHEIMER, PARKINSON, HUNTINGTON, ESCLEROSIS LATERAL AMIOTROFICA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99119539 | 1999-10-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20010648A1 true PE20010648A1 (es) | 2001-06-13 |
Family
ID=8239107
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2000001024A PE20010648A1 (es) | 1999-10-01 | 2000-09-28 | Derivados de quinolin-4-ilo amino u oxi |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US6440995B1 (es) |
| JP (1) | JP3523174B2 (es) |
| KR (1) | KR100398561B1 (es) |
| CN (1) | CN1181059C (es) |
| AR (1) | AR025882A1 (es) |
| AT (1) | ATE281436T1 (es) |
| AU (1) | AU774363B2 (es) |
| BR (1) | BR0004548A (es) |
| CA (1) | CA2321324A1 (es) |
| CO (1) | CO5200789A1 (es) |
| CZ (1) | CZ20003575A3 (es) |
| DE (1) | DE60015471T2 (es) |
| ES (1) | ES2230017T3 (es) |
| HR (1) | HRP20000639A2 (es) |
| HU (1) | HUP0003861A3 (es) |
| ID (1) | ID27525A (es) |
| IL (1) | IL138777A0 (es) |
| MA (1) | MA26752A1 (es) |
| NO (1) | NO20004892L (es) |
| NZ (1) | NZ507141A (es) |
| PE (1) | PE20010648A1 (es) |
| PL (1) | PL342876A1 (es) |
| PT (1) | PT1088818E (es) |
| SG (1) | SG164268A1 (es) |
| TR (1) | TR200002831A3 (es) |
| ZA (1) | ZA200005239B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6831087B2 (en) * | 2001-11-09 | 2004-12-14 | Hoffmann-La Roche Inc. | Pyridine substituted isoquinoline derivatives |
| RU2285693C2 (ru) * | 2002-02-13 | 2006-10-20 | Ф.Хоффманн-Ля Рош Аг | Производные пиридина и хинолина, способ их получения, фармацевтическая композиция, применение соединений для лечения заболеваний, ассоциированных с dpp-iv |
| WO2006017326A1 (en) * | 2004-07-13 | 2006-02-16 | Glaxo Group Limited | Antibacterial agents |
| AU2008304231A1 (en) * | 2007-09-27 | 2009-04-02 | Albany Molecular Research, Inc. | Isoindoline compounds for the treatment of spinal muscular atrophy and other uses |
| US9840500B2 (en) * | 2014-06-16 | 2017-12-12 | Fundación Para La Investigación Médica Aplicada | Compounds as dual inhibitors of histone methyltransferases and DNA methyltransferases |
| WO2016061280A1 (en) | 2014-10-14 | 2016-04-21 | La Jolla Institute Of Allergy & Immunology | Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof |
| KR20170074178A (ko) * | 2015-12-21 | 2017-06-29 | 제이엔씨 주식회사 | 중합성 액정 화합물, 조성물, 그 액정 중합막류 및 이들의 용도 |
| CN105646462B (zh) * | 2016-01-19 | 2019-04-05 | 河南大学 | 芸香宁碱衍生物、其制备方法及应用 |
| US11066420B2 (en) | 2017-05-01 | 2021-07-20 | Sanford Burnham Prebys Medical Discovery Institute | Inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP) and uses thereof |
| TW202304917A (zh) * | 2021-03-26 | 2023-02-01 | 美商賽迪拉治療股份有限公司 | Ｔｅａｄ抑制劑及其用途 |
| JP2023139414A (ja) * | 2022-03-22 | 2023-10-04 | 東レ株式会社 | フェナントロリン誘導体の製造方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE440008C (de) | 1924-03-29 | 1927-05-04 | I G Farbenindustrie Akt Ges | Verfahren zur Darstellung von Chinolinderivaten |
| US4560692A (en) | 1984-07-18 | 1985-12-24 | Hoffmann-La Roche Inc. | 4-Piperidino-2-phenylquinolines |
| GB9125515D0 (en) | 1991-11-29 | 1992-01-29 | Merck Sharp & Dohme | Therapeutic agents |
| US5441963A (en) | 1991-12-20 | 1995-08-15 | Merrell Dow Pharmaceuticals | Potentiation of NMDA antagonists |
-
2000
- 2000-09-11 US US09/658,934 patent/US6440995B1/en not_active Expired - Fee Related
- 2000-09-26 ES ES00120890T patent/ES2230017T3/es not_active Expired - Lifetime
- 2000-09-26 NZ NZ507141A patent/NZ507141A/en unknown
- 2000-09-26 PT PT00120890T patent/PT1088818E/pt unknown
- 2000-09-26 AT AT00120890T patent/ATE281436T1/de not_active IP Right Cessation
- 2000-09-26 DE DE60015471T patent/DE60015471T2/de not_active Expired - Fee Related
- 2000-09-26 MA MA26068A patent/MA26752A1/fr unknown
- 2000-09-27 CO CO00073351A patent/CO5200789A1/es not_active Application Discontinuation
- 2000-09-27 AU AU61324/00A patent/AU774363B2/en not_active Ceased
- 2000-09-27 CZ CZ20003575A patent/CZ20003575A3/cs unknown
- 2000-09-27 CA CA002321324A patent/CA2321324A1/en not_active Abandoned
- 2000-09-27 SG SG200005551-7A patent/SG164268A1/en unknown
- 2000-09-28 HR HR20000639A patent/HRP20000639A2/hr not_active Application Discontinuation
- 2000-09-28 ZA ZA200005239A patent/ZA200005239B/xx unknown
- 2000-09-28 IL IL13877700A patent/IL138777A0/xx unknown
- 2000-09-28 CN CNB001292013A patent/CN1181059C/zh not_active Expired - Fee Related
- 2000-09-28 AR ARP000105102A patent/AR025882A1/es not_active Application Discontinuation
- 2000-09-28 PE PE2000001024A patent/PE20010648A1/es not_active Application Discontinuation
- 2000-09-29 BR BR0004548-9A patent/BR0004548A/pt not_active IP Right Cessation
- 2000-09-29 JP JP2000298078A patent/JP3523174B2/ja not_active Expired - Fee Related
- 2000-09-29 PL PL00342876A patent/PL342876A1/xx not_active Application Discontinuation
- 2000-09-29 HU HU0003861A patent/HUP0003861A3/hu unknown
- 2000-09-29 NO NO20004892A patent/NO20004892L/no unknown
- 2000-09-29 ID IDP20000849D patent/ID27525A/id unknown
- 2000-09-29 TR TR2000/02831A patent/TR200002831A3/tr unknown
- 2000-09-29 KR KR10-2000-0057259A patent/KR100398561B1/ko not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| NO20004892L (no) | 2001-04-02 |
| ES2230017T3 (es) | 2005-05-01 |
| KR100398561B1 (ko) | 2003-09-19 |
| CZ20003575A3 (cs) | 2001-11-14 |
| ATE281436T1 (de) | 2004-11-15 |
| HUP0003861A2 (hu) | 2001-10-28 |
| DE60015471D1 (de) | 2004-12-09 |
| ID27525A (id) | 2001-04-12 |
| PL342876A1 (en) | 2001-04-09 |
| SG164268A1 (en) | 2010-09-29 |
| MA26752A1 (fr) | 2004-12-20 |
| US6440995B1 (en) | 2002-08-27 |
| HRP20000639A2 (en) | 2001-06-30 |
| ZA200005239B (en) | 2001-04-16 |
| CN1290698A (zh) | 2001-04-11 |
| AU6132400A (en) | 2001-04-05 |
| AR025882A1 (es) | 2002-12-18 |
| AU774363B2 (en) | 2004-06-24 |
| DE60015471T2 (de) | 2005-10-27 |
| HUP0003861A3 (en) | 2002-09-30 |
| TR200002831A2 (tr) | 2001-04-20 |
| BR0004548A (pt) | 2001-05-29 |
| IL138777A0 (en) | 2001-10-31 |
| TR200002831A3 (tr) | 2001-04-20 |
| CN1181059C (zh) | 2004-12-22 |
| HU0003861D0 (en) | 2000-12-28 |
| KR20010050738A (ko) | 2001-06-15 |
| JP2001097952A (ja) | 2001-04-10 |
| NO20004892D0 (no) | 2000-09-29 |
| CO5200789A1 (es) | 2002-09-27 |
| PT1088818E (pt) | 2005-03-31 |
| NZ507141A (en) | 2002-05-31 |
| CA2321324A1 (en) | 2001-04-01 |
| JP3523174B2 (ja) | 2004-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20020514A1 (es) | Aminas heterociclicas y fenilazacicloalcanos sustituidos para el tratamiento del sindrome de piernas inquietas | |
| AR248393A1 (es) | Compuestos de n-arilglutarimidas herbicidas y composicion que los comprende. | |
| PE20010648A1 (es) | Derivados de quinolin-4-ilo amino u oxi | |
| PE20050482A1 (es) | Derivados de dihidrobenzofuranilo alcanamida | |
| PE20020753A1 (es) | Heteroaromaticos fusionados como activadores de la glucoquinasa | |
| PE20020917A1 (es) | Derivados de imidazol como bloqueadores del receptor n-metil-d-aspartato | |
| SE8106642L (sv) | Piperazinylbensoheterocykliska foreningar och forfarande for framstellning derav | |
| PE20001467A1 (es) | Derivados de 4-fenilpiridina como antagonistas del receptor de neuroquinina | |
| PE20071223A1 (es) | Procedimiento de preparacion de derivados de acil-amino-alquilen-amida | |
| DK0595851T3 (da) | Fremgangsmåde til fremstilling af sertralin-mellemprodukter | |
| AR018917A1 (es) | Compuestos derivados de adenosina que son agonistas en el receptor adenosina a1, proceso para su preparacion, composiciones farmaceuticas que los contienen. | |
| PE20030268A1 (es) | Compuestos de pirazina como ligandos del receptor de 5-ht | |
| ES2054309T3 (es) | Compuestos de urea sustituida y su preparacion y uso. | |
| PE20010964A1 (es) | Derivados de tiazolilamida | |
| DE69523159D1 (de) | Sulfonamidderivate von azolonen als anti-helicobacter-mittel | |
| PE20020063A1 (es) | Bis-arilsulfonas como ligandos del receptor de 5-ht | |
| PE20070007A1 (es) | Metodos para sintetizar derivados de 6-alquilaminoquinolina | |
| PE20011212A1 (es) | Compuestos para el tratamiento de la fibromialgia y el sindrome de fatiga cronica | |
| PE20001084A1 (es) | Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas | |
| PE20060483A1 (es) | Compuestos heterociclicos como antagonistas de nk1 | |
| PE20020253A1 (es) | Derivados de 3-azabiciclo[3.1.0]hexano como ligandos de receptores opiaceos | |
| PE20020906A1 (es) | Inhibidores de peptido-deformilasa | |
| AR039111A1 (es) | Tiopirimidinas e isotiazolpirimidinas inhibidoras de quinasas | |
| PE27497A1 (es) | Derivados de 1,5 benzodiazepina | |
| AR033300A1 (es) | Compuestos de cefem |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |